The New England journal of medicine
-
Randomized Controlled Trial Comparative Study Clinical Trial
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. ⋯ In the treatment of metastatic malignant melanoma, dacarbazine plus tamoxifen is more effective than dacarbazine alone, as indicated by both the response rate and the median survival; the difference in efficacy is among women.